ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
100,763.98
-1.49%
S&P 500
5,975.38
0.55%
Dow Jones
42,706.56
0.00%
US Dollar vs Yen
157.7455
0.00%
Brent Oil
76.675
0.74%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) ニュース

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:IONS
日付受信時刻ニュースソース見出しコード企業名
2025/01/0707 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/12/2706 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/12/2104 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/12/2008 : 28PR Newswire (US)TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1510 : 34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1507 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1507 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1507 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1322 : 55Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1306 : 17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1306 : 16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1306 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0900 : 52Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0721 : 05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0706 : 06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0701 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0621 : 01PR Newswire (US)Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman SyndromeNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0621 : 00PR Newswire (US)Ionis reports third quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0423 : 44PR Newswire (US)Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAENASDAQ:IONSIonis Pharmaceuticals Inc
2024/10/2320 : 05PR Newswire (US)Ionis to hold third quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/10/2115 : 08PR Newswire (US)WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

最近閲覧した銘柄

AMEX
XLE
Energy Select Sector SPDR
FX
USDEUR
US Dollar vs Euro
CCOM
US100
US Tech 100
COIN
DOGEUSD
Dogecoin
SPI
SP500
S&P 500
NASDAQ
TSLA
Tesla
USI
USTECH100
US Tech 100
COIN
BTCUSD
Bitcoin
NASDAQ
AAPL
Apple
COIN
XRPUSD
Ripple
AMEX
XLV
Health Care Select Sector
PM
XAUUSD
Gold vs US Dollar
AMEX
XLF
Financial Select Sector
NASDAQ
AMZN
Amazon.com
FX
USDJPY
US Dollar vs Yen
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有